

### **Contents**

- 01 Performance review
- 02 Statements of comprehensive income
- 03 Headline earnings
- 03 Normalised EBITDA
- 04 Statements of financial positior
- 05 Statement of changes in equity
- 06 Statements of cash flow
- 07 Accounting policies
- bc Our hospitals

### Performance review

Group Revenue grew by 17% increasing to R1 496.8 million compared to R1 274.7 million in 2018. The increase relates to both an increase in Paid Patient Days (PPDs) (7%) and Rand per Patient Day (RPPD) (10%).

The Group has adopted IFRS 16 Leases from 01 March 2019 but has not restated comparatives for the 2019 reporting period as permitted under the modified retrospective approach in the standard. On adoption of IFRS 16, the company recognised lease liabilities in relation to leases which had previously been classified as operating leases under the principles of IAS 17 Leases. The lease liability is initially measured at the present value of the contractual lease payments, discounted using the rate implicit in the lease. The remaining liability at the end of each reporting date is the present value of the remaining lease payments. The corresponding right-of-use assets have been recognised on the balance sheet based on the corresponding lease liability. The right-of-use assets are depreciated over the remaining lease terms. The change in accounting policy has had the following effect on results for the first 6 months of the year:

- Increase in EBITDA of R19 million
- Increase in depreciation of R8.7 million
- Increase in Interest paid of R14.9 million
- Decrease in profit after tax of R3.2 million
- Increase in Property Plant and equipment of R264.8 million
- Increase in long term lease liability of R279.2 million

After the implementation of IFRS 16, normalised EBITDA increased by 28% to R296.9 million (2019: R231.4 million) while net profit after tax increased by 37% to R119.7 million (2019: R87.8 million). If we exclude the impact of IFRS 16, normalised EBITDA has increased by 20% on a like for like basis.

The EBITDA margin improved to 20% from 18% in the prior year. The 2% margin improvement can be attributed to the IFRS 16 implementation (1%), the significant increase in revenue and as well as the cost containment measures introduced in the Group during the year.

The Group's hospitals reported mostly improved results for the first 6 months of the financial year, where greater than average performance growth was noted in both revenue and normalised EBITDA.

Net Interest expense amounted to R64.7 million (2018: R68.8 million) for the first half of the year. This decrease is due to improved rates on the renegotiated RMB facility in the current year.

The Group's property, plant and equipment increased in value to R3 146 million (2018: R3 077 million). The increase relates to a new paediatric ward and adult high care unit at EHHC as well as general replacement and growth capex at all facilities.

Trade debtors have increased during the first half of the year due to the increased work for the Ministry of Health in Botswana and other state related work with longer payment cycles than the medical aid funds. Working capital management is however managed actively through our dedicated working capital management team and we are satisfied that the book (net of provisions) is collectable.

#### **Prospects**

The Group expects real growth in earnings, but at a slower rate than the first half. This is in line with the seasonal nature of the industry.

The first half of the year has been an extremely busy and fruitful period for Lenmed. We would like to convey our appreciation for all who have contributed to Lenmed's continuing success.

## Statements of comprehensive income

	Crava		
		Group	
Figures in R'000	Unaudited six months ended 31 August 2019	Unaudited six months ended 31 August 2018	Audited year ended 28 February 2019
Profit and Loss Revenue Cost of sales	1 496 768 (427 807)	1 270 701 (358 656)	2 546 127 (715 256)
GROSS PROFIT	1 068 961	912 045	1 830 871
Other income Operating costs	37 446 (869 389)	34 423 (761 295)	80 563 (1 547 764)
PROFIT BEFORE INTEREST AND TAXATION	237 018	185 173	363 670
Share of profit from associates Investment income Finance costs  PROFIT BEFORE TAXATION	1184 1 671 (81 208)	916 1 404 (70 222) 117 271	1 850 4 422 (141 206) 228 736
Taxation	(38 943)	(29 480)	(53 242)
PROFIT FOR THE PERIOD	119 722	87 791	175 494
Other comprehensive income Items that may be reclassified subsequently to profit and loss Foreign currency translation reserve	40 194	95 030	76 182
Total other comprehensive income for the period	40 194	95 030	76 182
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	159 916	182 821	251 676
Profit for the period attributable to: Non-controlling interests Lenmed Investments Ltd equity holders	22 925 96 798 119 723	15 012 72 779 87 791	32 735 142 759 175 494
Total comprehensive income for the period attributable to: Non-controlling interests Lenmed Investments Ltd equity holders	24 759 135 157	18 164 164 657	35 577 216 099
cermica investments are equity flotters	159 916	182 821	251 676

# Headline earnings

	Group		
Figures in R'000	Unaudited six months ended 31 August 2019	Unaudited six months ended 31 August 2018	Audited year ended 28 February 2019
Profit for the period attributable to Lenmed Less: Profit on disposal of assets net of tax Less: currencies losses and gains	96 798 - (977)	72 779 - -	142 759 487 (690)
	95 821	72 779	142 556

### **Normalised EBITDA**

	Group		
Figures in R'000	Unaudited six months ended 31 August 2019	Unaudited six months ended 31 August 2018	Audited year ended 28 February 2019
EBITDA Loss/(profit) on disposal of assets Currencies (losses) and gains	296 976 - (1 357)	231 489 - (4 807)	446 471 684 (1 921)
	295 619	226 682	445 234

# Statements of financial position

		Group		
Figures in R'000	Unaudited six months ended 31 August 2019	Unaudited six months ended 31 August 2018	Audited year ended 28 February 2019	
Assets				
Non-Current Assets Property, plant and equipment Lease Assets Goodwill Intangible assets Investment in associates Deferred taxation	2 806 816 264 825 312 888 26 573 3 881 77 343	2 696 532 - 312 888 18 969 6 523 56 294	2 738 129 - 312 888 26 573 4 497 67 208	
	3 492 326	3 091 206	3 149 295	
Current Assets Inventory Trade and other receivables Taxation Cash and cash equivalents	67 694 816 981 26 058 50 807	71 593 614 020 24 087 63 509	63 749 666 519 22 454 70 874	
	961 540	773 209	823 596	
TOTAL ASSETS	4 453 866	3 864 415	3 972 891	
Equity and Liabilities Equity and Reserves Stated capital Other Reserves Accumulated profits Non-controlling interests	426 006 179 427 1 329 306 193 504 2 128 243	426 006 165 018 1 183 899 153 598 1 928 521	426 006 141 067 1 240 261 169 746 1 977 080	
Non-Current Liabilities Long term liabilities Loans from minorities Lease liabilities Deferred taxation	1 088 592 39 488 279 201 260 526 1 667 807	1 053 743 54 145 229 422 1 337 310	1 017 651 42 496 236 520 1 296 667	
Current Liabilities Trade payables, other payables and provisions Current portion of long term liabilities Taxation Bank overdraft	448 212 131 107 18 452 60 045	427 362 122 689 2 661 45 872	418 333 150 349 12 065 120 397	
	657 816	598 584	699 144	
TOTAL EQUITY AND LIABILITIES	4 453 866	3 864 415	3 972 891	

# Statement of changes in equity

				Group			
Figures in R	Stated capital	Foreign currency translation reserve	Share- based payment reserve	Accumulated profits	Equity attributable to Group	Non- controlling interest	Total
BALANCE AT 31 AUGUST 2018	426 006	159 605	5 413	1 183 899	1774 922	153 598	1 928 521
Profit for the period Other comprehensive income Share-based payment accrual Increase in investment related to	- - -	- (18 537) -	- - (5 413)	59 568 - -	59 568 (18 537) (5 413)	17 723 (310)	77 291 (18 847) (5 413)
non-controlling interests share buy-back Dividends BALANCE AT 28 FEBRUARY 2019	- - 426 006	- - 141 068	- - -	(3 207) - 1 240 260	(3 207) - 1 807 333	(960) (305) 169 746	(4 167) (305) 1 977 080
Profit for the period Other comprehensive income IFRS 16 transitional adjustment Dividends Increase in investment related to non-controlling interests share buy-back	- - - -	38 359 - -	- - - -	96 798 - (5 144) - (661)	96 798 38 359 (5 144) - (661)	22 925 1 834 (1 945) (806)	119 722 40 194 (7 089) (806)
BALANCE AT 31 AUGUST 2019	426 006	179 427	_	1 331 253	1 936 685	191 558	2 128 243

## Statements of cash flows

		Group	
Figures in R'000	Unaudited six months ended 31 August 2019	Unaudited six months ended 31 August 2018	Audited year ended 28 February 2019
Cash flows from operating activities Operating cash flow before working capital changes Working capital changes	277 240	234 242	438 674
Decrease/(increase) in trade and other receivables (Increase)/ decrease in inventory Increase in trade and other payables	(150 466) (3 945) 31 878	(13 329) (5 644) 58 766	(51 770) 4 551 32 170
Cash generated by operating activities Investment income Finance costs Income tax paid	154 707 1 671 (66 332) (19 534)	274 035 1 404 (70 222) (24 674)	423 625 4 422 (141 206) (42 611)
NET CASH FROM OPERATING ACTIVITIES	70 512	180 543	244 230
Cash flows from investing activities Property, plant and equipment acquired Proceeds on disposal of Property, plant and equipment Acquisition of business	(77 261) - -	(114 094) (3 550)	(181 869) 5 (3 550)
NET CASH UTILISED IN INVESTING ACTIVITIES	(77 261)	(117 644)	(185 414)
Cash flows from financing activities Proceeds from shares issued Net loans (repaid)/raised Dividends paid Non-controlling interests share buy-back	- 48 693 (806) (854)	- (15 546) - -	- (72 064) (306) (4 167)
NET CASH GENERATED BY FINANCING ACTIVITIES Increase/(Decrease) in cash and cash equivalents Translation movement Cash and cash equivalents at beginning of the year	47 033 40 284 - (49 523)	(15 546) 47 353 - (29 716)	(76 537) -17 721 (2 082) (29 720)
CASH AND CASH EQUIVALENTS AT END OF THE YEAR	(9 239)	17 637	(49 523)

## **Accounting policies**

#### 1. Basis of preparation

The condensed unaudited consolidated interim financial statements for the six months ended 31 August 2019 have been prepared in accordance with the framework concepts and measurement and recognition requirements of International Financial Reporting Standards (IFRS), IAS 34 Interim Financial Reporting Standards, the SAICA Financial Reporting Guidelines as issued by the Accounting Practices Committee, Financial Pronouncements as issued by the Financial Reporting Standards Council and the Companies Act of South Africa. This report was compiled under the supervision of Fredre Meiring CA (SA). The Board takes full responsibility for the preparation of these financial results.

The accounting policies used in the preparation of these results are in accordance with IFRS and consistent in all material respect with those of the previous annual financial statements, except for leases accounted for in accordance with IFRS 16. Comparative information has not been restated as the Group has applied the modified retrospective approach of IFRS 16. The interim financial statements have been prepared on the historical cost basis.

The preparation of financial statements in conformity with IFRS requires management to make judgements, estimates and assumptions that may affect the application of policies and reported amounts of assets, liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision only affects that period, or in the period of the revision and future periods if the revision affects both current and future periods. The interim results have not been reviewed or audited by the Group's external independent auditors, PKF Durban.

#### 2. Change in Accounting Policy

The financial statements have been prepared in accordance with International Financial Reporting Standards on a basis consistent with the prior year except for the addition of the following standard.

The Group has adopted IFRS 16 Leases from 01 March 2019 but has not restated comparatives for the 2019 reporting period as permitted under the modified retrospective approach in the standard. On adoption of IFRS 16, the company recognised lease liabilities in relation to leases which had previously been classified as operating leases under the principles of IAS 17 Leases. The lease liability is initially measured at the present value of the contractual lease payments, discounted using the rate implicit in the lease. The remaining liability at the end of each reporting date is the present value of the remaining lease payments. The corresponding right-of-use assets have been recognised on the balance sheet based on the corresponding lease liability. The right-of-use assets are depreciated over the remaining lease terms. The change in accounting policy has had the following effect on results:

	Unaudited six months ended 31 August 2019
Statement of financial position	
Property, Plant and Equipment	264 825
Lease Liabilities	279 201
Retained income (Transitional adjustment)	(7 089)
Profit and Loss	
Depreciation	8 672
Finance costs	14 876

### Our hospitals

#### Ahmed Kathrada Private Hospital

K43 Highway, Extension 8, Lenasia Gauteng

#### **Bokamoso Private Hospital**

Plot 2435, Mmopane Block 1, Gaborone, Botswana

#### **Daxina Private Hospital**

1682 Impala Street, Lenasia South, Gauteng

#### **Ethekwini Hospital and Heart Centre**

11 Riverhorse Road, Riverhorse Valley Business Estate, Queen Nandi Drive, Durban, KwaZulu-Natal

#### **Kathu Private Hospital**

Frikkie Meyer Street, Kathu

#### La Verna Private Hospital

1 Convent Road, Ladysmith, KwaZulu-Natal

#### **Maputo Private Hospital**

Rua do Rio Inhamiara, Sommerschield II, Maputo, Mozambique

#### **Randfontein Private Hospital**

Ward Street Ext. Randfontein, Gauteng

#### **Shifa Private Hospital**

482 Randles Road, Sydenham, Durban, KwaZulu-Natal

#### **Zamokuhle Private Hospital**

128 Flint Mazibuko Street, Hospital View, Tembisa, Gauteng

#### **Royal Hospital and Heart Centre**

Corner Welgevonden and Jacobus Smit Street, Royldene, Kimberley



www.lenmedlimited.com

#### **Contact details**

#### **Registered office:**

2nd Floor Fountainview House, Constantia Office Park, Corner 14th Avenue and Hendrik Potgieter Road, Constantia Kloof

info@lenmedlimited.com